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Objectives. We sought to determine the epidemiology and
clinical significance of paroxysmal supraventricular tachycardia
(PSVT) in the general population.
Background. Current knowledge of PSVT has been derived
primarily from otherwise healthy patients referred to specialized
centers.
Methods. We used the resources of the Marshfield Epidemio-
logic Study Area, a region covering practically all medical care
received by its 50,000 residents. A review of 1,763 records identi-
fied prevalent cases as of July 1, 1991 and all new cases of PSVT
diagnosed from that day until June 30, 1993. A mean follow-up
period of 2 years was completed in all incident patients. Patients
without other cardiovascular disease were labeled as having “lone
PSVT.”
Results. The prevalence was 2.25/1,000 persons and the inci-
dence was 35/100,000 person-years (95% confidence interval, 23 to
47/100,000). Other cardiovascular disease was present in 90% of
males and 48% of females (p 5 0.0495). Compared with patients
with other cardiovascular disease, those with lone PSVT were
younger (mean 37 vs. 69 years, p 5 0.0002), had a faster PSVT
heart rate (mean 186 vs. 155 beats/min, p 5 0.0006) and were
more likely to have their condition first documented in the
emergency room (69% vs. 30%, p 5 0.0377). The onset of
symptoms occurred during the childbearing years in 58% of
females with lone PSVT versus 9% of females with other cardio-
vascular disease (p 5 0.0272).
Conclusions. There are ;89,000 new cases/year and 570,000
persons with PSVT in the United States. In the general popula-
tion, there are two distinct subsets of patients with PSVT: those
with other cardiovascular disease and those with lone PSVT. Our
data suggest etiologic heterogeneity in the pathogenesis of PSVT
and the need for more population-based research on this common
condition.
(J Am Coll Cardiol 1998;31:150–7)
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To date, there are no published reports of paroxysmal su-
praventricular tachycardia (PSVT) in the general population.
PSVT is generally a regular, narrow complex tachyarrhythmia
frequently encountered in clinical practice (1–6). It is the most
common arrhythmia in the Wolff-Parkinson-White (WPW)
syndrome. Even in the absence of overt pre-excitation, re-
entry through the atrioventricular (AV) node or a concealed
bypass tract accounts for ;90% of all PSVT (1). The
electrophysiologic-morphologic substrates responsible for both
AV node reentry tachycardia (AVNRT) and AV reentry
tachycardia (AVRT) are thought to be present from birth
(1,7). This congenital defect theory is supported by the obser-
vation that most patients reported on (8–12) are young healthy
persons referred to tertiary care centers for treatment of
intractable PSVT. Despite the widespread utilization of radio-
frequency ablation as a curative and cost-effective therapy for
patients with refractory tachycardia (13–18), there are no data
on its role in more typical cases.
The purpose of our investigation was to determine the
epidemiology and clinical significance of PSVT in the general
population. Population studies provide incidence, prevalence
and demographic data on unselected cases and thus improve
our understanding of associated conditions (19) and facilitate
good clinical decisions (20).
Methods
Population-based epidemiologic research is feasible in cen-
tral Wisconsin because almost all health care is provided by
Marshfield Clinic or St. Joseph’s Hospital. These institutions
share a common system of medical records including informa-
tion on all inpatient and outpatient medical care encounters.
The Marshfield Epidemiologic Study Area (MESA) has been
established to conduct epidemiologic studies and population-
based health research. MESA is a zip code–defined region
with ;50,000 residents in and around Marshfield, Wisconsin.
Validation studies (21) have shown that MESA ascertains
100% of deaths, 94% of hospital discharges and 92% of
outpatient medical visits among area residents. The population
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data base is updated daily, allowing longitudinal follow-up of
individual persons. The study protocol, including the abstrac-
tion form designed to obtain the pertinent information from
the records, was approved by our Institutional Review Board.
Potential cases of PSVT occurring among MESA residents
from January 1, 1979 through June 30, 1993 were initially
identified by reviewing Marshfield Clinic’s computerized diag-
nostic data base. Since 1979, the International Classification of
Diseases, 9th Revision, Clinical Modification (ICD-9-CM) has
been used to code diagnoses. A physician reviewed the records
of all potential cases and completed a standard abstraction
form. Standard ECG criteria for PSVT were employed: 1)
paroxysmal occurrence, 2) normal QRS complex configuration
or preexisting bundle branch block, 3) variation in successive
RR intervals #40 ms, 4) ventricular rate $120 beats/min, 5) no
evidence of AV dissociation, and 6) no identifiable P waves
preceding the QRS complex during tachycardia (22–24). All
ECG tracings identified as potentially eligible were confirmed
by cardiac electrophysiologists. During the 100,000 person-
years of observation, ;13,000 ECGs and rhythm strips, 500
Holter monitors and 250 ambulatory event recordings were
obtained from the MESA residents. Incident and prevalent
cases satisfying the ECG criteria were included in the study if
the documented PSVT was clinically significant, defined as an
event causing symptoms or requiring short- or long-term
therapy.
Incidence. To identify newly diagnosed cases of PSVT, we
reviewed the records of all MESA residents who had a first
occurrence of any of the following ICD-9-CM codes from July
1, 1991 through June 30, 1993: 1) 426.7, anomalous AV
excitation; 2) 427.0, PSVT; 3) 427.2, paroxysmal tachycardia,
unspecified; 4) 427.6, premature beats, unspecified; 5) 427.89,
other cardiac arrhythmias; 6) 427.9, cardiac arrhythmia, un-
specified; 7) 785.0, tachycardia, unspecified; or 8) 785.1, palpi-
tations. To ensure complete ascertainment, we also employed
two codes of the Current Procedural Terminology (CPT)
system: 1) 93620, comprehensive electrophysiologic evalua-
tion; and 2) 93650, intracardiac catheterization-ablation of
arrhythmogenic focus or tracts. However, these two codes
identified no additional potential cases not identified by the
eight ICD-9-CM codes.
Prevalence. A review of the incident cases indicated that
91% of PSVT cases could be identified by using four ICD-
9-CM codes (426.7, 427.0, 427.89 and 427.9). Therefore, we
used these codes to identify potential prevalent PSVT cases.
Prevalence was determined as of July 1, 1991. We identified
2,223 persons living in the MESA on that date who had
received one or more of the four codes between January 1,
1979 and June 30, 1991. To estimate the proportion of
potential prevalent cases that could be confirmed by ECG
review, we selected a stratified random sample of 600 potential
prevalent cases for chart review. We randomly selected 150
persons in each of the following groups: 1) males ,65 years, 2)
females ,65 years, 3) males $65 years, and 4) females $65 years.
Clinical course. A mean follow-up interval of 24 months
(range 1 to 38) was achieved for all incident cases. For the 28
patients living at the time of last follow-up, the minimal and
mean periods of observation were 12 and 26 months, respec-
tively. Data collection was conducted by reviewing medical
records of the incident patients who had been seen either as an
inpatient or an outpatient at least once during 2 months before
June 30, 1995. The four patients not seen during this period
were contacted by telephone and asked to respond to a
structured interview to complete a questionnaire specifically
designed for this study.
Data analysis. The entire population of MESA, including
persons of all ages, was considered at risk for development of
PSVT. The number of verified incident cases was divided by
the total number of person-years of observation for all MESA
residents. Age- and gender-adjusted rates were calculated by
using the 1990 U.S. census as the standard. We used Poisson
regression to estimate relative risks and confidence intervals
for PSVT according to age and gender. Prevalence was esti-
mated by adjusting the number of potential prevalent cases
identified through the computer data base by the proportion of
confirmed cases in the chart review sample. The denominator
for the prevalence proportion was the number of persons living
in the MESA on July 1, 1991. Associations between gender and
associated cardiovascular disease (CVD) were analyzed with
the Fisher exact test. Univariate comparisons of heart rates
and associated CVD were made with the Wilcoxon rank sum
test. The Kaplan-Meier method was used to estimate the
percent of patients remaining free of PSVT recurrence in each
month of follow-up (25). A p value # 0.05 was considered
statistically significant. All statistical calculations were gener-
ated with SAS software (version 6.08) (SAS Institute, Inc.) and
StatXact statistical software (STATXACT TURBO, 1992,
CYTEL Software Corporation).
Results
Prevalence. A review of the computerized diagnoses data
base identified 2,223 potential prevalent cases. Reviewing the
records and electrocardiographic (ECG) tracings of a sub-
sample of 600 patients confirmed 31 prevalent cases of PSVT.
The verification proportion differed by age and gender. Ac-
counting for the sampling design, we estimated that as of July
Abbreviations and Acronyms
AV 5 atrioventricular
AVNRT 5 atrioventricular node reentry
AVRT 5 atrioventricular reentry
CI 5 confidence interval
CVD 5 cardiovascular disease
ECG 5 electrocardiogram, electrocardiographic
ICD-9-CM 5 International Classification of Diseases,
9th Revision, Clinical Modification
MESA 5 Marshfield Epidemiologic Study Area
PSVT 5 paroxysmal supraventricular tachycardia
WPW 5 Wolff-Parkinson-White
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1, 1991, the crude proportion of MESA residents who had
received a diagnosis of PSVT over the previous 12 years was
2.25/1,000 persons (Table 1).
Incidence. A total of 1,163 patients were classified as
potential new cases of PSVT. A review of all records and ECGs
of all 1,163 patients confirmed 33 incident cases of PSVT. Only
13 (39%) of the 33 incident cases would have been detected
had we limited our screening to those identified by code 427.0,
the specific ICD-9-CM code for PSVT. Overall, the incidence
rate of documented PSVT in MESA was 35/100,000 person-
years (Table 2).
Age, gender and other associated CVD. Table 3 shows the
clinical characteristics and main features of the incident pa-
tients. The mean age at the time of initial PSVT documentation
was 57 years (range: infancy to 90 years). Among the 33 incident
patients, 23 (70%) were females. Females had a risk of develop-
ment of PSVT two times greater than that of males (relative
risk 2.0, 95% confidence interval [CI] 1.0 to 4.2). The risk of
development of PSVT was more than five times greater in
residents $65 years than in those ,65 years old (relative risk
5.3, 95% CI 2.7 to 10.5).
Other CVD was considered present only if its existence
before the initial diagnosis of PSVT could be established from
chart abstraction. All patients had ECG tracings during tachy-
cardia and sinus rhythm. In addition, 70% had other diagnostic
cardiac studies, including two-dimensional echocardiogram
and cardiac catheterization. CVD was considered present in
those persons with a documented diagnosis of hypertension,
coronary artery disease, congestive heart failure, valvular heart
disease, atrial fibrillation/flutter, sick sinus syndrome, congen-
ital heart disease or pericarditis. CVD was present in 20 (61%)
of the 33 incident patients, occurring in 90% of males and 48%
of females (p 5 0.0495) (Table 4). Hypertension was present in
15 patients, coronary artery disease in 7, congestive heart
failure in 6, atrial fibrillation in 6; ECG evidence of WPW
syndrome was present in only 1 subject. Thirteen (39%) of
patients with newly diagnosed PSVT had no CVD and were
labeled as having “lone PSVT.” Of the 23 female incident
patients, 12 (52%) had lone PSVT, accounting for all but 1 of
the 13 patients with lone PSVT. The onset of symptoms of
PSVT occurred during the childbearing age (15 to 50 years) in
7 of 12 females with lone PSVT but in only 1 of 11 females with
other associated CVD (p 5 0.0272). All males with other CVD
also had the onset of symptoms late in life, after the age of 50
years. Thus, in patients with CVD, gender did not influence the
age of onset of symptoms. Subjects with associated CVD were
older than those with lone PSVT (mean 69 vs. 37 years, p 5
0.0002). For the 33 incident cases, the average heart rate
during the initial documented episode of PSVT was 167
beats/min. As a group, patients with CVD had slower tachy-
cardia rates than did those with lone PSVT (mean heart rate
during PSVT, 155 vs. 186 beats/min, p 5 0.0006).
Clinical characteristics. Twenty-one incident patients
(64%) had symptoms suggestive of PSVT before initial ECG
documentation, including 8 who had symptoms for ,1 year
and 13 who had symptoms for .1 year before diagnosis. In 8 of
the remaining 12 patients (24% of all incident patients), PSVT
was documented during their first symptomatic episode. Four
asymptomatic incident patients satisfied our definition of clin-
ically significant PSVT because they required treatment for
their arrhythmia. At initial diagnosis, 6 (30%) of 20 patients
with CVD had PSVT documented in the emergency room,
compared with 9 (69%) of 13 patients with lone PSVT (p 5
0.0377) (Table 4). At initial presentation, four patients (12%)
were taking cardioactive drugs capable of slowing or prevent-
ing PSVT. Two patients presented with hemodynamic instabil-
ity (hypotension, cardiovascular collapse or syncope) during
the tachycardia. At last follow-up, 78% of incident patients had
been referred to a cardiologist or electrophysiologist.
Electrophysiologic findings and long-term treatments.
Electrophysiologic studies were performed in six patients,
documenting AVNRT in five and orthodromic AVRT in the
patient with the WPW syndrome. Radiofrequency ablation was
performed in four patients: three with CVD and one with lone
PSVT. At last follow-up, 67% of patients with CVD and 47%
with lone PSVT were taking antiarrhythmic agents.
Table 1. Prevalence of Paroxysmal Supraventricular Tachycardia per
1,000 Persons by Age and Gender
Age Males Females Total
,65 yr 0.95 2.37 1.65
$65 yr 9.69 3.65 6.16
Total 1.94 2.56 2.25
Adjusted 2.05* 2.53* 2.29†
*Age adjusted to the 1990 U.S. census. †Age and gender adjusted to the
1990 U.S. census.
Table 2. Incidence Rates of Paroxysmal Supraventricular Tachycardia per 100,000 Person-Years by
Age and Gender
Age
(yr)
Males Females Total
No. Rate No. Rate No. Rate (95% CI)
#19 1 7 3 21 4 13 (0–27)
20–64 4 15 10 38 14 27 (13–40)
$65 5 98 10 139 15 122 (60–184)
Total (95% CI) 10 21 (8–35) 23 48 (28–67) 33 35 (23–47)
Adjusted (95% CI) 24 (9–39)* 46 (27–65)* 36 (23–48)†
*Age adjusted to the 1990 U.S. census. †Age and gender adjusted to the 1990 U.S. census. CI 5 confidence interval.
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Clinical course. Based on a mean follow-up interval of 24
months for the 33 incident cases, the cumulative observation
period was 771 person-months. During that time, six patients
(four females) had a total of eight documented recurrences.
The probability of experiencing a recurrence by the end of year
2 of follow-up was 0.20 (95% CI 0.06 to 0.35) (Fig. 1). No
predictors of recurrence were identified. Among patients with
a recurrence, all but one experienced their first recurrence within
12 months of diagnosis and one presented with hemodynamic
instability. Five patients died during follow-up, none secondary to
PSVT. All deaths occurred in subjects with other CVD (mortality
rate in that group 25% at 2 years). Specific causes of death
included intracranial hemorrhage in an 84-year old woman,
congestive heart failure in a 56-year old man, pneumonia in a
90-year old woman, stage IV non-Hodgkin’s lymphoma in a
54-year old man and pancreatic cancer in a 70-year old man.
Discussion
This study, the first population-based investigation of
PSVT, challenges many existing beliefs regarding this common
Table 3. Clinical Characteristics of the 33 Incident Patients
Case
No.
Age (yr)/
Gender
PSVT Rate
(beats/min)
Initial
Documentation
Long-Term Therapy
Duration of
Symptoms Associated CVDMedical RFA
1 83/F 157 Office None None HTN
2 73/F 148 Office Yes $1 yr HTN
3 75/F 138 Office Yes None HTN
4 56/M 152 Wards Yes 1st episode CHF, CAD, HTN
5 90/F 158 Wards Yes None CAD, HTN, AFib
6 60/M 152 Wards Yes $1st yr CHF, HTN, AFl
7 78/M 140 Wards Yes 1st episode CHF, CAD, VSD
8 68/F 150 Wards Yes 1st episode CHF, HTN, AI, MR, AFib, SSS
9 69/F 167 Wards Yes 1st episode AS, AFib
10 53/M 158 Holter monitor None $1 yr Pericarditis, MVP
11 43/F 170 Holter monitor Yes ,1 yr HTN, AFib
12 65/F 170 Holter monitor None $1 yr HTN
13 66/M 178 Holter monitor Yes $1 yr HTN
14 68/M 207 Holter monitor Yes $1 yr HTN
15 69/M 140 ER Yes ,1 yr HTN, SSS
16 63/M 130 ER Yes None CHF, HTN
17 82/F 130 ER Yes $1 yr CAD, HTN, AFib
18 82/F 146 ER Yes 1st episode CHF, CAD, HTN, MR
19 69/M 143 ER Yes ,1 yr CAD, AFib, AFl
20 60/F 164 ER Yes ,1 yr WPW, CAD, Ebstein
21 14/M 230 Holter monitor None $1 yr —
22 8/F 200 Holter monitor None ,1 yr —
23 20/F 167 EP lab Yes ,1 yr —
24 50/F 200 EP lab Yes $1 yr —
25 26/F 172 ER Yes $1 yr —
26 71/F 200 ER Yes $1 yr —
27 36/F 168 ER None 1st episode —
28 62/F 190 ER Yes $1 yr —
29 0.3/F 240 ER None ,1 yr —
30 39/F 135 ER None ,1 yr —
31 76/F 182 ER Yes 1st episode —
32 46/F 160 ER Yes 1st episode —
33 39/F 180 ER Yes $1 yr —
AFib 5 atrial fibrillation; AFl 5 atrial flutter; AI 5 aortic insufficiency; AS 5 aortic stenosis; CAD 5 coronary artery disease; CHF 5 congestive heart failure;
CVD 5 cardiovascular disease; Ebstein 5 Ebstein’s anomaly; EP lab 5 electrophysiology laboratory; ER 5 emergency room; F 5 female; HTN 5 hypertension; M 5
male; MR 5 mitral regurgitation; MVP 5 mitral valve prolapse; PSVT 5 paroxysmal supraventricular tachycardia; RFA 5 radiofrequency ablation; SSS 5 sick sinus
syndrome; VSD 5 ventricular septal defect; WPW 5 Wolff-Parkinson-White syndrome.
Table 4. Comparison of Incident Patients With Lone Paroxysmal
Supraventricular Tachycardia and With Paroxysmal Supraventricular
Tachycardia and Cardiovascular Disease
PSVT and CVD Lone PSVT p Value
Patients (no.) 20 13
Females (%) 55% 92% 0.0495
Mean age (yr) 69 37 0.0002
Mean PSVT rate (beats/min) 155 186 0.0006
Initial PSVT in ER 30% 69% 0.0377
Onset of symptoms in females
at age 15–50 years (%)
9% 58% 0.0272
Abbreviations as in Table 3.
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arrhythmia. Our findings show that patients with PSVT and
the condition itself are different in the general population
than in tertiary care centers. We believe that our study has
identified important but previously unrecognized features of
this common entity. This undistorted view of PSVT has
changed our perception of typical patients and their ex-
pected course.
Epidemiology. There are no previous studies on the inci-
dence and prevalence of PSVT in the general population.
When our rates are adjusted by age and gender to the
population of the U.S., the incidence of PSVT is estimated to
be 36/100,000 persons per year, and the prevalence is 2.29/
1,000 persons. If our results could be extrapolated to the entire
U.S. population, we estimate there would be nearly 89,000 new
cases/year and ;570,000 persons with PSVT in this country. In
the Manitoba follow-up study (26), healthy males selected for
aircrew training had an incidence rate of regular narrow QRS
complex tachycardias of 17/100,000 persons per year. In our
series, males in the age group 20 to 64 years had a similar
incidence of 15/100,000 persons per year. The observation that
our overall incidence is more than twofold greater than that
reported in the Manitoba study can be explained by differences
in the populations studied. Our design identified subsets of
patients at a significantly greater risk of PSVT than that of
healthy young males. Females had a risk of development of
PSVT two times greater than that of males. Residents 65 years
or older had more than five times the risk of development of
PSVT than that of younger residents.
By identifying virtually all persons with PSVT in the area,
we avoided errors of selection bias. In contrast to patients with
PSVT reported from specialized arrhythmia centers, the un-
selected persons in our study were more likely to be older, to
be female and to have other CVD, and they were at lower risk
of experiencing refractory PSVT (Table 5). Subjects in our
series had a mean age of 57 years, whereas the subjects studied
by Jackman et al. (28) and Sintetos et al. (38) had a mean age
of 41 and 42 years, respectively. Associated CVD was found in
61% of our subjects with newly diagnosed PSVT. CVD has
Figure 1. Cumulative percent of patients free of documented recur-
rence of PSVT during follow-up.
Table 5. Demographic Features of Patients With Paroxysmal Supraventricular Tachycardia in Present
and Previous Studies
Patients
Mean Age
(yr) Male/Female
CVD
Other Than WPW
Recurrence
Rate (%)
Calkins et al. (9) 106 43 49/57 10 (1%) N/A
Kay et al. (12) 608 40 302/306 N/A N/A
Lindsay et al. (27) 59 44 18/41 8 (14%) N/A
Jackman et al. (28)* 80 42 24/56 14 (18%) 81% at 1 mo
Chen et al. (29) 408 47 264/144 56 (14%) N/A
Rodriguez et al. (30) 574 36 325/249 N/A N/A
Wu et al. (31) 100 48 37/63 6 (6%) N/A
Clair et al. (32)* 113 40 56/57 35 (31%) 75% at 3 mo
Wu et al. (33) 79 52 45/34 31 (39%) N/A
DiMarco et al. (34) 359 47 186/173 0 N/A
Bhandari et al. (35) 49 50 15/34 27 (55%) N/A
den Dulk et al. (36) 40 49 17/23 9 (22%) N/A
Giraudon et al. (37) 32 30 3/29 0 N/A
Sintetos et al. (38)* 34 42 23/11 10 (30%) 83% at 3 mo
Henthorn et al. (39)* 34 50 11/23 16 (47%) 25% at 2 mo
Dorian et al. (40) 121 51 35/86 N/A N/A
Hopson et al. (41) 67 41 33/34 33 (39%) N/A
Total 2,863 44 1,443/1,420 (16%) 71% at 3 mo
(referral centers) (females, 50%)
Present study 33 57 10/23 20 (61%) 6% at 3 mo,
(population based) (Females, 70%) 20% at 24 mo
*Studies used to calculate minimal recurrence rates at 3 months. Unless otherwise indicated, data are presented as
number (%) of patients. CVD 5 cardiovascular disease; EPS 5 electrophysiologic study; N/A 5 not available; RFA 5
radiofrequency ablation; WPW 5 Wolff-Parkinson-White syndrome.
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been reported in 1% to 25% of patients undergoing radiofre-
quency ablation for PSVT (27–29,42).
Unlike the more homogeneous group of mostly young
healthy patients reported from referral centers, we have found
that persons with PSVT in the general population fall into at
least two distinct clinical subsets: those with other CVD and
those without CVD (lone PSVT). Patients with lone PSVT are
more likely to be females, to be younger at the time of
diagnosis, to have had earlier onset of symptoms, to have faster
PSVT rates, to be identified in the emergency room setting and
to have a longer survival time. Among the estimated 89,000
subjects with new PSVT per year in the U.S., our data suggest
that ;54,000 probably have other CVD and 35,000 have lone
PSVT.
Clinical course. In the general population, frequently re-
curring, drug-refractory or hemodynamically destabilizing
PSVT is uncommon. During ;800 person-months of observa-
tion, our patients had eight documented recurrences of PSVT,
and only one of these was associated with symptoms suggestive
of hemodynamic instability. Documented recurrences oc-
curred in two patients (6%) at 3 months and in six patients
(20%) at 2 years. In four previous studies reporting on early
recurrences, 71% of patients had one or more recurrences at 3
months (Table 5). Whereas only one of our patients (3%) had
more than one recurrence in .2 years, Jackman et al. (28)
reported that 81% of their patients experienced at least one
episode every 30 days before radiofrequency ablation, and
Kalbfleisch et al. (15) described a frequency of 4.5 episodes/
month. Owing to the small number of patients and their benign
course, we were unable to identify predictors associated with
recurrence of PSVT.
Assuming that accessory AV connections and WPW syn-
drome were the most common morphologic substrates respon-
sible for PSVT, most of the early work on its mechanism
(43,44) excluded patients with overt pre-excitation. In one
study that did not exclude patients with overt pre-excitation
(45), WPW syndrome was found in 68 (57%) of 120 consecu-
tive patients admitted to the hospital for PSVT. Of the 45
patients in that series in whom the first attack occurred before
the age of 21, 73% had pre-excitation. Only one patient (3%)
in our series had WPW syndrome. We believe that the
misconception that this syndrome is the most common cause of
PSVT resulted from a systematic referral bias that preferen-
tially selected patients for hospital admission if they could be
identified and treated surgically, the only curative treatment
modality at the time. Patients with a delta wave during sinus
rhythm (WPW syndrome) or very fast PSVT (more frequently
seen in PSVT with retrograde conduction over an accessory
pathway) are more likely to be admitted to the hospital than
are those with a normal ECG during sinus rhythm and slower
heart rates during PSVT. The recent ability to perform cura-
tive radiofrequency ablation for almost all patients with PSVT
has shown that AVNRT, not WPW syndrome, is the most
common mechanism of PSVT.
Although AVNRT accounts for .60% of patients with
PSVT undergoing invasive testing, these patients rarely require
immediate hospital admission. AVRT, either in the setting of
WPW syndrome with overt pre-excitation or occurring by
means of retrograde conduction over a concealed accessory
pathway, is now known to account for only ;30% of PSVT.
Just as recent technologic advances have clarified the fre-
quency of the different underlying electrophysiologic mecha-
nisms in PSVT, we believe that epidemiologic studies can
dispel and challenge clinical misconceptions (46).
Severely affected patients are more likely to be referred to
tertiary care centers and to benefit from invasive procedures
(47). Medical decisions appropriate for such patients may not
be applicable to less seriously affected patients in the general
population. Cost-effectiveness analysis of competing therapeu-
tic strategies formulated for referral patients with incapacitat-
ing, drug-refractory PSVT may not be generalizable to persons
with the “same illness” in the general population (14). Recent
reviews (48,49) and the 1995 guidelines of the American Heart
Association/American College of Cardiology/North American
Society of Pacing and Electrophysiology (16) advocate invasive
electrophysiologic evaluation and radiofrequency ablation for
patients with symptomatic PSVT who prefer ablative therapy
over pharmacologic treatment. These guidelines have not
addressed how to best manage patients after their first docu-
mented episode of well tolerated PSVT. Our study findings
suggest the need for further investigation in the assessment of
optimal utilization of each of the therapeutic modalities avail-
able for PSVT. Given an average charge of $15,000/
radiofrequency ablation procedure (11), performing this pro-
cedure on the ;90,000 patients with new cases of clinically
significant PSVT each year in the U.S. would result in charges
of well over $1 billion/year. However, this investigation shows
that .60% of patients with PSVT in the general population
have other associated CVD, such as hypertension, coronary
artery disease or atrial fibrillation, for which chronic treatment
will be needed. These clinical conditions are frequently treated
with medications also used for PSVT, such as beta-adrenergic
blocking agents, calcium channel blocking agents or digoxin.
Given that three of four patients with PSVT in the general
population require long-term medical therapy or radiofre-
quency ablation, and given the potential increased risk of
PSVT in these patients, it may well be that the increased
utilization of ablation in the elderly is appropriate. Our group
(50) recently reported data quantitating the dramatic increase
in the use of radiofrequency ablation in the U.S. Medicare
population over the last few years. Only well designed prospec-
tive outcome studies will answer this important question.
Heterogeneity of PSVT. Our findings suggest the possibility
of etiologic heterogeneity in the pathogenesis of PSVT. As
previously noted, it is now well established that .90% of
patients with PSVT have AVNRT or AVRT as the mechanism
of PSVT. Both of these arrhythmias require the AV node for
their maintenance. Both of these conditions have been viewed
as congenital anomalies because it was believed that the
required substrate was present from birth (7). Our study, in
contrast, suggests that PSVT may be a heterogeneous disease
with different underlying mechanisms. This assertion is sup-
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ported by our finding that 91% of males, but only 50% of
females, with PSVT have associated CVD. Additional evi-
dence for a yet unrecognized etiologic mechanism of PSVT
comes from the 12 females in our study with lone PSVT. In
seven (58%) of these females the onset of symptoms occurred
during childbearing age, an infrequent occurrence (9%)
among females with underlying CVD (p 5 0.0272). Rosano et
al. (51) recently reported a strong correlation between epi-
sodes of PSVT and plasma concentration of ovarian hormones.
Thus, hormonal effects experienced after menarche may con-
tribute to the increased risk of PSVT observed in young
healthy women. The possibility that PSVT has a heterogeneous
etiology is also supported by recent reports (52) documenting
that different molecular abnormalities are responsible for the
condition currently labeled the familial long QT syndrome.
Limitations of the study. We minimized selection bias by
identifying practically all cases occurring in the entire popula-
tion of a defined geographic region. Although ICD-9-CM
coding of medical conditions may not be completely accurate,
we used a large set of codes to try to identify all possible PSVT
cases. Using eight ICD-9-CM and two CPT codes, we reviewed
nearly 1,200 charts to identify 33 incident cases of PSVT; thus,
it is unlikely that we missed many, if any, incident cases of
clinically significant PSVT during the study period. It is
possible, however, that we might have missed a small number
of cases, including atrial tachycardia, by using the ECG criteria
we adopted (22–24). In our review of all MESA residents who
underwent invasive electrophysiologic testing during the
100,000 person-years of observation, there were no cases of
unexplained wide complex tachycardia that presented exclu-
sively as rate-related bundle branch block. Given the limita-
tions in current technology and the nature of this intermittent
condition, complete ascertainment of PSVT in any population
would require continuous and long-term ECG monitoring of
all persons in the area, a study that is not likely to be feasible.
Diagnostic bias was minimized by having electrophysiologists
review the ECG tracings in all suspected cases to verify the
diagnosis according to standard criteria. For the incidence
study, the starting date coincided with the introduction of
radiofrequency ablation at our institutions. The 2-year time
interval, however, constrained the number of cases and limited
the statistical power. The MESA population is predominantly
white and rural. Although we are not aware of studies estab-
lishing racial, ethnic or residential predisposition to PSVT, our
results should be used cautiously to project to other population
groups.
More population-based studies are needed to enhance our
understanding of the epidemiology and health care resource
needs of patients with this and other common arrhythmias.
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